Other studies have reported PD-L1 positivity in 30–45% of breast cancers by varying criteria of epithelium and stromal cell staining using quantitative analysis of various monoclonal antibodies, and have reported that expression is higher in TNBC.28,29. This evidence concerns the gene CD274 and breast carcinoma.